A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy (NCT05696717)
CYPRESS
This trial is No longer recruiting
Registration number NCT05696717
Program & service
This trial is being run with the Brain service, and as part of the Neurology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Kelly Bertram
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR